MyMD doses 37 of 40 patients in Phase 2 trial of MYMD-1 for sarcopenia/frailty; no safety issues

Q/C TECHNOLOGIES, INC.

Safety Review Committee confirms no safety/toxicity issues with first 30 patients; unanimous vote to escalate to final dose level.
37 of 40 total patients randomized and dosed across four cohorts; only 3 patients away from dosing final patient.
Phase 2 double-blind, placebo-controlled study targets reduction of chronic inflammatory markers (IL-6, sTNFR-1) in patients aged 65+.
No FDA-approved treatments currently exist for sarcopenia/frailty; aging disorders market estimated at $600B by 2025.
Company planning early-stage trials for rheumatoid arthritis with MYMD-1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.